Continuous Glucose Monitoring in the Intensive Care Unit

Description

The aim of the proposed clinical trial is to study the use of the Dexcom G7 continuous glucose monitor (CGM) within the intensive care unit (ICU) environment. The overall goal is to validate the accuracy and practicality of the Dexcom G7 when used to assess glycemia in critically ill patients.

Conditions

Diabetes Mellitus

Talk to us

Study Overview

On this page

Study Details

Study overview

The aim of the proposed clinical trial is to study the use of the Dexcom G7 continuous glucose monitor (CGM) within the intensive care unit (ICU) environment. The overall goal is to validate the accuracy and practicality of the Dexcom G7 when used to assess glycemia in critically ill patients.

Continuous Glucose Monitoring in the Intensive Care Unit: Validation and Implementation

Continuous Glucose Monitoring in the Intensive Care Unit

Condition
Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

Worcester

UMass Memorial Medical Center, Worcester, Massachusetts, United States, 01605

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Persons with either type 1 or type 2 diabetes.
  • * Persons of either sex.
  • * Persons of any age over 18.
  • * Persons able to give informed consent or cognitively impaired adults whose legally authorized representative (LAR) can give informed consent.
  • * English or Spanish speaking adults.
  • * Persons unable to provide informed consent.
  • * Cognitively impaired persons whose LAR declines to provide informed consent.
  • * Patients receiving hydroxyurea, which interferes with sensor function.
  • * Patients receiving high dose acetaminophen (\> 4 gm/day), which interferes with sensor function.
  • * Anasarca affecting preferred areas for device placement (arm, upper buttocks, or thigh), which may interfere with sensor accuracy.
  • * Severe cachexia with absence of subcutaneous fat at preferred sensor placement sites, which might interfere with sensor accuracy.
  • * Persons who are pregnant.
  • * Prisoners.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Massachusetts, Worcester,

John P Mordes, MD, PRINCIPAL_INVESTIGATOR, UMass Chan Medical School

Study Record Dates

2024-12-30